BB Biotech AG (BBAGF) Fund Overview
BB Biotech AG (BBAGF) — price $76.06 (0.00%), as of the Nov 18, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
BB Biotech AG · BBAGF
BB Biotech AG is a Swiss-based investment company specializing in biotechnology investments. The company's strategy focuses on identifying and investing in companies with promising medications and diagnostics.
Price as of Nov 18, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $76.06 | |
| Change on the day | 0.00% | |
| 52-week range | $33.65 – $76.06 | |
| Price / earnings (trailing) | 2.71 | |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for BB Biotech AG (BBAGF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 16, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 16, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is BB Biotech AG (BBAGF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. BB Biotech AG (BBAGF) is the company analyzed here. It employs 10 people and is led by Daniel Koller. In Q3 FY2026 it reported revenue of CHF 92M and net income of CHF 170M.
What do the latest results show for BB Biotech AG (BBAGF)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of CHF 92M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | CHF 92M | CHF 170M | CHF 3.09 (diluted) |
| Q2 FY2026 | CHF 109M | CHF 449M | CHF 7.97 (diluted) |
| Q1 FY2026 | CHF 35M | -CHF 21M | -CHF 0.38 (diluted) |
| Q4 FY2025 | CHF 475M | CHF 472M | CHF 8.62 (diluted) |
What are the financial strengths and risks for BB Biotech AG (BBAGF)?
Short answer · as of
The distress and quality screens read Altman Z 81.71 · Piotroski F 5. Trailing ratios: ROE 36.6% · ROA 32.6% · earnings yield 37.7% · free-cash-flow yield 6.9%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BBAGF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BBAGF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: BBAGF Stock
These answers are editorial: 1 of these 1 answer is drawn from the BBAGF research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What are the main risks for BBAGF?
The main risks for BB Biotech AG (BBAGF) include regulatory and clinical trial risks associated with the biotechnology sector. The success of its portfolio companies depends on obtaining regulatory approvals and achieving positive clinical trial outcomes.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 8 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com